ATRCHealthcare · Medical Instruments & SuppliesThe 10 Wall Street analysts covering AtriCure, Inc. hold a median 12-month price target of $50 — -4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 2 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores AtriCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Issuance (63): The company has been issuing shares or taking on financing, diluting existing holders.
Size (32): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ATRC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −4.7% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2026 | Needham | Maintains | Buy | $45 → $64 |
| 27 Aug 2026 | Piper Sandler | Maintains | Overweight | $50 → $60 |
| 24 Aug 2026 | BTIG | Maintains | Buy | $45 → $55 |
| 28 July 2026 | UBS | Maintains | Buy | $55 → $50 |
| 28 July 2026 | UBS | Maintains | Buy | — |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | $53 → $55 |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 Feb 2026 | BTIG | Reiterates | Buy | — |
| 18 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 Feb 2026 | Citizens | Maintains | Market Outperform | — |
| 18 Feb 2026 | Oppenheimer | Downgrade | Perform | — |
| 18 Feb 2026 | UBS | Maintains | Buy | — |
| 12 Feb 2026 | Needham | Reiterates | Buy | — |
| 16 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 30 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2025 | Needham | Maintains | Buy | — |
| 30 Apr 2025 | BTIG | Maintains | Buy | — |
| 30 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Apr 2025 | Needham | Maintains | Buy | — |
| 30 Apr 2025 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATRC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, AtriCure, Inc. returned +50.9% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 28% of US stocks
Cheaper than 22% of US stocks
Cheaper than 3% of US stocks
Higher than 59% of US stocks
Higher than 51% of US stocks
Higher than 89% of US stocks
Higher than 58% of US stocks
Higher than 52% of US stocks
Higher than 48% of US stocks
Higher than 52% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AtriCure, Inc. has a market value of $2.5B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $569.6M. The latest quarter grew 12.8% year on year.
Net income over the same four quarters: $10.6M, a 1.9% net margin.
Diluted earnings per share, trailing twelve months: $0.21.
Free cash flow in the twelve months to 30 June 2026: $52.1M.
AtriCure, Inc. spent $12.3M on share buybacks and $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: 233.0×; forward P/E: 113.3× — the forward figure prices analyst consensus estimates, not reported earnings.
AtriCure, Inc. employs 1,350 people — $422K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AtriCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
This Zacks Investment Research piece examines how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year, offering a year-to-date performance comparison of the two medical stocks.
Why it matters — AtriCure watchers can gauge how the company's shares stack up against a direct peer and the broader medical sector in 2025.
AtriCure, Inc. announced it will participate in the 2026 Wells Fargo Health Care Conference, with management scheduled to take part in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time.
Why it matters — A fireside chat at a major healthcare conference gives AtriCure's management a platform to present the company to investors and industry participants, offering visibility to those following ATRC.
AtriCure is expanding its surgical platform across appendage management, ablation, and postoperative pain care through products such as AtriClip, EnCompass, and cryoSPHERE, providing the company a diversified revenue base. The piece notes that catheter-based PFA competition could pressure the company's growth and margin potential as a risk.
Why it matters — ATRC watchers would care because the article highlights both the company's broadening surgical product portfolio and a competitive PFA risk that could affect future growth and margins.
AtriCure reported continued growth across its atrial fibrillation, left atrial appendage management, and postsurgical pain-management businesses, citing new product adoption, expanding procedure volumes, and progress in clinical trials.
Why it matters — ATRC watchers would care because the company is signaling broadening momentum across multiple business lines and advancing clinical programs.
Two AtriCure directors reduced their shareholdings following a strong quarter. One transaction involved 3,500 shares sold at $38.42 per share, totaling $134,470 and reducing that director's total equity holdings by 20%, per the Form 4.
Why it matters — ATRC watchers would care because insider selling can signal director confidence and is relevant when assessing insider activity after a strong quarterly performance.
The 10 Wall Street analysts covering AtriCure, Inc. have a median 12-month price target of $50, with estimates ranging from $36 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering AtriCure, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AtriCure, Inc. 95 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, AtriCure, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies -4.7% from the last close, and Ticker Nerd's factor model ranks AtriCure, Inc. 95 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AtriCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATRC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $60 over the next 12 months.
AtriCure, Inc. returned +50.9% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain.
The most recent item we track (Zacks Investment Research, 27 Aug 2026): "Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?". This Zacks Investment Research piece examines how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year, offering a year-to-date performance comparison of the two medical stocks.
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain. Its portfolio includes ablation systems, left atrial appendage exclusion devices, cryoablation products, and related surgical instruments used in cardiac, thoracic, and electrophysiology procedures. AtriCure’s products are designed for use by cardiothoracic surgeons, electrophysiologists, and medical centers that perform open, minimally invasive, and hybrid cardiac surgeries. The company serves healthcare providers in the United States and international markets, supporting procedure workflows in hospitals and specialized surgical settings. Founded in 2000 and headquartered in Mason, Ohio, AtriCure focuses on device-based therapies that address important needs in rhythm management and surgical pain control.
CEO Mr. Michael H. Carrel · 1,350 employees · United States · https://www.atricure.com
